Comparison · NCT03654768-4bf0d2fc
Single Agent TKI vs TKI + Ruxolitinib: Drug Compliance
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Single Agent TKI vs TKI + Ruxolitinib: Drug Compliance. Trial comparisons, record NCT03654768-4bf0d2fc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03654768-4bf0d2fc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.973 | 0.862 | 0.995 | wilson | |
| Risk in group 2 | 0.861 | 0.713 | 0.939 | wilson | |
| Risk difference, group 1 minus group 2 | 0.112 | -0.024 | 0.261 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.13 | 0.981 | 1.3 | log | |
| Odds ratio, group 1 over group 2 | 5.81 | 0.643 | 52.4 | log | |
| Number needed to treat, for one more participant with the outcome on Single Agent TKI than on TKI + Ruxolitinib | 8.94 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Single Agent TKI | Patients receive bosutinib PO daily or dasatinib PO daily or nilotinib PO BID or imatinib PO daily on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. | 36 | 37 | OG000 |
| Group 2 | TKI + Ruxolitinib | Patients receive ruxolitinib phosphate PO BID on days 1-90, and bosutinib PO daily or dasatinib PO daily or nilotinib PO BID or imatinib PO daily on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. | 31 | 36 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Drug Compliance
- Description
- Will be summarized descriptively, results presented as number of participants that were fully compliant for all cycles that they received treatment.
- Time frame
- Up to 5 years
- Population
- This population includes the 73 participants who were eligible and received at least one dose of study treatment. 37 in the Single Agent TKI arm and 36 in the TKI + Ruxolitnib arm.
Source ClinicalTrials.gov
Trial
- Title
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
- NCT number
- NCT03654768
- Phases
- PHASE2
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- Bosutinib, Dasatinib, Laboratory Biomarker Analysis, Nilotinib, Ruxolitinib, Imatinib
- Lead sponsor
- SWOG Cancer Research Network
- Results first posted
- 2025-12-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03654768?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03654768-4bf0d2fc